An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Pembrolizumab (Keytruda) in Combination With Lenvatinib (Lenvima): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Dostarlimab (Jemperli): CADTH Reimbursement Recommendation: Indication: Dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.
Entrectinib (Rozlytrek): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation and with no satisfactory treatment options [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on